WITH the price of Mounjaro set to rise and concerns about long-term affordability and access, many may be looking to turn to alternative treatments, like Wegovy. But how do the two weight loss

Novo Nordisk shares climbed after the U.S. Food and Drug Administration approved a new indication for the Danish drugmaker’s blockbuster Wegovy medicine to treat a serious fatty liver disease. Shares in Novo Nordisk rose as much as 5% in early European trading Monday,